VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO 2021 | Surgical outcomes from the Phase III CheckMate 816 trial

Jonathan Spicer, MD, PhD, McGill University, Montreal, Canada, outlines surgical outcomes from CheckMate 816 (NCT02998528), a Phase III study evaluating nivolumab and platinum-doublet chemotherapy versus chemotherapy alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC). In this study, neoadjuvant nivolumab and chemotherapy did not impede feasibility and timing of surgery, nor the extent of completeness of resection when compared to chemotherapy alone. In addition, patients in the experimental arm demonstrated significant improvement in pathological complete response, representing a potential neoadjuvant option for patients with stage IB to IIIA resectable NSCLC. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter